Susan Vitale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan Vitale has a total of 457 co-authors. Here are the top co-authors by number of shared publications:
- Frederick L. Ferris
National Eye Institute, National Institutes of Health, Bethesda, Maryland
10 shared publications - David Steven Friedman
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts
9 shared publications - Hatice Nida Sen
National Institutes of Health
6 shared publications Sheila West
6 shared publications- Hugh Ringland Taylor
Indigenous Eye Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
5 shared publications - Mary Frances Cotch
Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Maryland, USA
5 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (2) , 101022
Changes in Vision-Related Quality of Life before and after Geographic Atrophy Development in Age-Related Eye Disease Study Participants
- 26 November 2025
- Published by Elsevier in Ophthalmology Science
- Vol. 6 (2) , 101022
Open AccessChanges in Vision-Related Quality of Life before and after Geographic Atrophy Development in Age-Related Eye Disease Study Participants
- 1 December 2021
- Published by Elsevier in Ophthalmology
- Vol. 128 (12) , A3
Editorial Board
- Open Access
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 138 (6) , 610-617
Association of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity
Age-related macular degeneration (AMD) is the most common cause of loss of visual acuity among older individuals in high-income countries.1-3 Therapies for AMD have focused on the late forms of AMD, neovascular (NV) AMD and geographic atrophy (GA). Although in the past decade anti–vascular endothelial growth factor agents have markedly improved the visual outcome of those with NV AMD,4-6 there is still no effective therapy for GA associated with AMD. Therapies, including complement inhibitors, visual cycle modulators, anti-inflammatory and immunosuppressive agents, and others, have been evaluated for the treatment of established GA. Laser photocoagulation of drusen in eyes with intermediate AMD also proved to be ineffective in reducing the progression to late AMD.7 A recent randomized clinical trial8 of subthreshold nanosecond laser treatment also found no overall beneficial treatment effect on AMD, although a post hoc subgroup analysis demonstrated a possible beneficial effect in eyes with large drusen and without atrophy or reticular pseudodrusen.
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 138 (6) , 610-617
Open AccessAssociation of 2-Year Progression Along the AREDS AMD Scale and Development of Late Age-Related Macular Degeneration or Loss of Visual Acuity
Age-related macular degeneration (AMD) is the most common cause of loss of visual acuity among older individuals in high-income countries.1-3 Therapies for AMD have focused on the late forms of AMD, neovascular (NV) AMD and geographic atrophy (GA). Although in the past decade anti–vascular endothelial growth factor agents have markedly improved the visual outcome of those with NV AMD,4-6 there is still no effective therapy for GA associated with AMD. Therapies, including complement inhibitors, visual cycle modulators, anti-inflammatory and immunosuppressive agents, and others, have been evaluated for the treatment of established GA. Laser photocoagulation of drusen in eyes with intermediate AMD also proved to be ineffective in reducing the progression to late AMD.7 A recent randomized clinical trial8 of subthreshold nanosecond laser treatment also found no overall beneficial treatment effect on AMD, although a post hoc subgroup analysis demonstrated a possible beneficial effect in eyes with large drusen and without atrophy or reticular pseudodrusen.
- 1 January 2020
- Published by Elsevier in Ophthalmology Retina
- Vol. 4 (1) , 3-12
Visual Acuity Outcomes after Anti–Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration
- 1 January 2020
- Published by Elsevier in Ophthalmology Retina
- Vol. 4 (1) , 3-12
Visual Acuity Outcomes after Anti–Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration
- 1 December 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (12) , 1726-1728
Usefulness of Routine Lyme Screening in Patients with Uveitis
- 1 December 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (12) , 1726-1728
Usefulness of Routine Lyme Screening in Patients with Uveitis
- 1 July 2019
- Published by Elsevier in Experimental Eye Research
- Vol. 184, 24-29
PEDF peptides promote photoreceptor survival in rd10 retina models
- 1 July 2019
- Published by Elsevier in Experimental Eye Research
- Vol. 184, 24-29
PEDF peptides promote photoreceptor survival in rd10 retina models
- Top Cited PapersOpen Access
- 1 February 2019
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 60 (3) , M20-M30
IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies
Purpose: We provide a standardized set of terminology, definitions, and thresholds of myopia and its main ocular complications. Methods: Critical review of current terminology and choice of myopia thresholds was done to ensure that the proposed standards are appropriate for clinical research purposes, relevant to the underlying biology of myopia, acceptable to researchers in the field, and useful for developing health policy. Results: We recommend that the many descriptive terms of myopia be consolidated into the following descriptive categories: myopia, secondary myopia, axial myopia, and refractive myopia. To provide a framework for research into myopia prevention, the condition of “pre-myopia” is defined. As a quantitative trait, we recommend that myopia be divided into myopia (i.e., all myopia), low myopia, and high myopia. The current consensus threshold value for myopia is a spherical equivalent refractive error ≤ −0.50 diopters (D), but this carries significant risks of classification bias. The current consensus threshold value for high myopia is a spherical equivalent refractive error ≤ −6.00 D. “Pathologic myopia” is proposed as the categorical term for the adverse, structural complications of myopia. A clinical classification is proposed to encompass the scope of such structural complications. Conclusions: Standardized definitions and consistent choice of thresholds are essential elements of evidence-based medicine. It is hoped that these proposals, or derivations from them, will facilitate rigorous, evidence-based approaches to the study and management of myopia.
- 1 February 2019
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 60 (3) , M20-M30
Top Cited PapersOpen AccessIMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies
Purpose: We provide a standardized set of terminology, definitions, and thresholds of myopia and its main ocular complications. Methods: Critical review of current terminology and choice of myopia thresholds was done to ensure that the proposed standards are appropriate for clinical research purposes, relevant to the underlying biology of myopia, acceptable to researchers in the field, and useful for developing health policy. Results: We recommend that the many descriptive terms of myopia be consolidated into the following descriptive categories: myopia, secondary myopia, axial myopia, and refractive myopia. To provide a framework for research into myopia prevention, the condition of “pre-myopia” is defined. As a quantitative trait, we recommend that myopia be divided into myopia (i.e., all myopia), low myopia, and high myopia. The current consensus threshold value for myopia is a spherical equivalent refractive error ≤ −0.50 diopters (D), but this carries significant risks of classification bias. The current consensus threshold value for high myopia is a spherical equivalent refractive error ≤ −6.00 D. “Pathologic myopia” is proposed as the categorical term for the adverse, structural complications of myopia. A clinical classification is proposed to encompass the scope of such structural complications. Conclusions: Standardized definitions and consistent choice of thresholds are essential elements of evidence-based medicine. It is hoped that these proposals, or derivations from them, will facilitate rigorous, evidence-based approaches to the study and management of myopia.
- 1 January 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (1) , 6-9
Choosing Core Outcomes for Use in Clinical Trials in Ophthalmology: Perspectives from Three Ophthalmology Outcomes Working Groups
- 1 January 2019
- Published by Elsevier in Ophthalmology
- Vol. 126 (1) , 6-9
Choosing Core Outcomes for Use in Clinical Trials in Ophthalmology: Perspectives from Three Ophthalmology Outcomes Working Groups
- Open Access
- 1 April 2018
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 59 (5) , 1953-1963
Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity
Purpose: As optical coherence tomography (OCT) minimum intensity (MI) analysis provides a quantitative assessment of changes in the outer nuclear layer (ONL), we evaluated the ability of OCT-MI analysis to detect hydroxychloroquine toxicity. Methods: Fifty-seven predominantly female participants (91.2% female; mean age, 55.7 ± 10.4 years; mean time on hydroxychloroquine, 15.0 ± 7.5 years) were enrolled in a case-control study and categorized into affected (i.e., with toxicity, n = 19) and unaffected (n = 38) groups using objective multifocal electroretinographic (mfERG) criteria. Spectral-domain OCT scans of the macula were analyzed and OCT-MI values quantitated for each subfield of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. A two-sample U-test and a cross-validation approach were used to assess the sensitivity and specificity of toxicity detection according to OCT-MI criteria. Results: The medians of the OCT-MI values in all nine of the ETDRS subfields were significantly elevated in the affected group relative to the unaffected group (P < 0.005 for all comparisons), with the largest difference found for the inner inferior subfield (P < 0.0001). The receiver operating characteristic analysis of median MI values of the inner inferior subfields showed high sensitivity and high specificity in the detection of toxicity with area under the curve = 0.99. Conclusions: Retinal changes secondary to hydroxychloroquine toxicity result in increased OCT reflectivity in the ONL that can be detected and quantitated using OCT-MI analysis. Analysis of OCT-MI values demonstrates high sensitivity and specificity for detecting the presence of hydroxychloroquine toxicity in this cohort and may contribute additionally to current screening practices.
- 1 April 2018
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 59 (5) , 1953-1963
Open AccessOptical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity
Purpose: As optical coherence tomography (OCT) minimum intensity (MI) analysis provides a quantitative assessment of changes in the outer nuclear layer (ONL), we evaluated the ability of OCT-MI analysis to detect hydroxychloroquine toxicity. Methods: Fifty-seven predominantly female participants (91.2% female; mean age, 55.7 ± 10.4 years; mean time on hydroxychloroquine, 15.0 ± 7.5 years) were enrolled in a case-control study and categorized into affected (i.e., with toxicity, n = 19) and unaffected (n = 38) groups using objective multifocal electroretinographic (mfERG) criteria. Spectral-domain OCT scans of the macula were analyzed and OCT-MI values quantitated for each subfield of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. A two-sample U-test and a cross-validation approach were used to assess the sensitivity and specificity of toxicity detection according to OCT-MI criteria. Results: The medians of the OCT-MI values in all nine of the ETDRS subfields were significantly elevated in the affected group relative to the unaffected group (P < 0.005 for all comparisons), with the largest difference found for the inner inferior subfield (P < 0.0001). The receiver operating characteristic analysis of median MI values of the inner inferior subfields showed high sensitivity and high specificity in the detection of toxicity with area under the curve = 0.99. Conclusions: Retinal changes secondary to hydroxychloroquine toxicity result in increased OCT reflectivity in the ONL that can be detected and quantitated using OCT-MI analysis. Analysis of OCT-MI values demonstrates high sensitivity and specificity for detecting the presence of hydroxychloroquine toxicity in this cohort and may contribute additionally to current screening practices.
- 20 February 2018
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 33 (5) , 605-607
Can your patients with heart failure see? The prevalence of visual impairment among adults with heart failure
- 20 February 2018
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 33 (5) , 605-607
Can your patients with heart failure see? The prevalence of visual impairment among adults with heart failure